Larimar Therapeutics, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 48/100
What the filing says
Larimar hired John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026 with an annual base salary of $560,000, a one-time signing bonus of $35,000, target annual bonus of 40% of base salary, 800,000 stock options (25% vesting at year 1, then 75% over 36 months), and 50,000 restricted stock units (vesting over 4 years). A First Amendment added whistleblower protections. No specific counterparty other than the executive or financial terms beyond compensation are disclosed.
Why this rating
Routine executive hire. Total comp ~$595K cash + equity is material (~0.6% of $94.7M market cap), but CEO hiring is ordinary business. Equity grant dilutes existing holders but is standard incentive practice.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.